What are Pacific Biosciences of California's total assets?

Pacific Biosciences of California (PACB) holds $782.4M in total assets, down 9.1% year over year.

How much debt does Pacific Biosciences of California have?

Pacific Biosciences of California carries $59.3M in total debt against $2.4M of shareholders' equity, a debt-to-equity ratio of 25.06.

How much cash does Pacific Biosciences of California have?

Pacific Biosciences of California holds $57.9M in cash and equivalents.

Can Pacific Biosciences of California cover its short-term obligations?

Its current ratio is 5.65 — current assets exceed current liabilities.

Where does Pacific Biosciences of California's balance sheet data come from?

Every line is extracted from Pacific Biosciences of California's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Pacific Biosciences of California PACB Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$65.26M+13.3%	$57.59M-68.5%	$182.63M-44.4%	$328.31M-29.5%
Short-term investments	$215.8M-35.5%	$334.56M-25.9%	$451.51M+1.0%	$447.23M-24.8%
Restricted cash	$20K-97.1%	$690K+130%	$300K0.0%	$300K-40.0%
Accounts receivable, net	$35.45M+28.8%	$27.52M-24.8%	$36.62M+94.9%	$18.79M-22.5%
Inventories	$81.4M-0.2%	$81.52M+43.8%	$56.68M+12.5%	$50.38M+105%
Raw materials	$38.64M-14.6%	$45.27M+124%	$20.17M-16.5%	$24.14M+202%
Work in process	$27.05M+22.0%	$22.17M-5.4%	$23.44M+66.7%	$14.06M+63.3%
Finished goods	$15.71M+11.6%	$14.08M+7.7%	$13.07M+7.3%	$12.18M+52.3%
Prepaid expenses and other current assets	$10.79M-42.5%	$18.78M+10.2%	$17.04M+65.6%	$10.29M+39.2%
Total current assets	$375.05M-24.3%	$495.68M-33.2%	$742.05M-12.9%	$852.07M-22.6%
Property and equipment, net	$24.15M-20.8%	$30.51M-16.3%	$36.43M-12.4%	$41.58M+27.9%
Accumulated depreciation	$406.42M+999%	$36.97M+287%	$9.56M-85.3%	$64.99M+15.5%
Operating lease right-of-use assets	$41.7M+159%	$16.09M-50.6%	$32.59M-18.0%	$39.76M-14.7%
Goodwill	$317.76M0.0%	$317.76M-31.3%	$462.26M+12.8%	$409.97M0.0%
Intangible assets, net	$15.12M-96.1%	$389.57M-14.8%	$456.98M+11.4%	$410.25M+3,637%
Other non-current assets	$8.77M-5.7%	$9.31M-29.9%	$13.27M+26.1%	$10.53M+800%
Available-for-sale securities	——	——	——	$69.93M-42.7%
Total assets	$784.08M-37.8%	$1.26B-27.8%	$1.75B-1.2%	$1.77B-12.0%
Accounts payable	$20.77M+25.2%	$16.59M+10.1%	$15.06M+25.2%	$12.03M+9.3%
Accrued expenses	$2.03M-37.0%	$3.22M-61.3%	$8.33M+15.1%	$7.23M-71.4%
Deferred revenue	$15.94M+14.9%	$13.86M-15.2%	$16.34M-46.4%	$30.5M+178%
Operating lease liabilities, current	$448K-95.5%	$10.03M+4.5%	$9.59M+7.9%	$8.89M+15.3%
Contract liabilities	$3.93M-33.4%	$5.9M+6.7%	$5.53M+208%	$1.79M-92.8%
Total current liabilities	$72.83M+9.9%	$66.3M-30.2%	$95.03M-63.9%	$263.34M+267%
Operating lease liabilities, non-current	$56.59M+279%	$14.91M-52.8%	$31.61M-23.0%	$41.07M-17.8%
Other non-current liabilities	$0-100%	$546K-27.3%	$751K-42.2%	$1.3M-62.5%
Total liabilities	$778.73M+4,064%	$18.7M-4.3%	$19.55M-88.6%	$172.09M+1.4%
Preferred stock	$0—	$0—	$0—	$0—
Common stock	1B+340,036%	294K+9.7%	268K+18.1%	227K-100.0%
Additional paid-in capital	$2.7B+1.7%	$2.65B+4.5%	$2.54B+21.0%	$2.1B+4.5%
Retained earnings	-$2.7B-25.4%	-$2.15B-16.8%	-$1.84B-20.0%	-$1.53B-25.8%
Accumulated other comprehensive income (loss)	$457K+8.3%	$422K+92.7%	$219K+105%	-$4.77M-338%
Total stockholders' equity	$5.35M-98.9%	$506.59M-27.8%	$701.3M+24.6%	$562.9M-28.8%
Total liabilities and stockholders' equity	$784.08M-37.8%	$1.26B-27.8%	$1.75B-1.2%	$1.77B-12.0%
Available-for-Sale Debt Securities - Amortized Cost	$279.05M-28.4%	$389.51M-38.3%	$631.2M-18.8%	$777.08M—
Available-for-Sale Debt Securities - Fair Value by Maturity	——	——	——	——
Available-for-Sale Debt Securities - Fair Value (Maturing Within 1 Year)	——	——	——	——
Available-for-Sale Debt Securities - Single Maturity Date	——	——	——	——
Other Inventory, Net	$32.11M+41.0%	$22.77M—	——	——
Deferred Tax Assets and Other Non-Current Assets	$8.77M-5.7%	$9.31M-29.9%	$13.27M+26.1%	$10.53M+800%
Finite-Lived Intangible Assets - Expected Amortization Expense (Year One)	——	——	——	$745K+1.6%
Finite Lived Intangible Assets - Gross	$421.54M+2.4%	$411.54M0.0%	$411.54M+3,467%	$11.54M+1.6%
Net Investment in Lease	$41.7M+159%	$16.09M-50.6%	$32.59M-18.0%	$39.76M-14.7%
Intangible assets — net	$15.12M-96.0%	$374.57M-6.8%	$401.98M+3,824%	$10.25M-6.7%
Other intangible assets—net	$15.12M-96.1%	$389.57M-14.8%	$456.98M+11.4%	$410.25M-0.2%
Operating lease right-of-use assets	$41.7M+159%	$16.09M-50.6%	$32.59M-18.0%	$39.76M-14.7%
Other non-current assets	$8.77M-5.7%	$9.31M-29.9%	$13.27M+26.1%	$10.53M+800%
Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)	$215.8M-35.5%	$334.56M-25.9%	$451.51M+1.0%	$447.23M-23.4%
Operating Lease Right-of-Use Assets in Other Assets	$41.7M+159%	$16.09M-50.6%	$32.59M-18.0%	$39.76M-14.7%
Software and Technology Licenses, Net	$8.77M-5.7%	$9.31M-29.9%	$13.27M+26.1%	$10.53M+800%
Accrued Progress Collections and Price Adjustments	$3.93M-33.4%	$5.9M+6.7%	$5.53M+208%	$1.79M-92.8%
Other Commercial Liabilities	$33.65M+48.9%	$22.6M-50.6%	$45.71M+40.2%	$32.6M-10.1%
Accrued Liabilities, Current	$33.65M+48.9%	$22.6M-50.6%	$45.71M+40.2%	$32.6M-10.1%
Other accrued liabilities	$2.03M-37.0%	$3.22M-61.3%	$8.33M+15.1%	$7.23M+25.6%
Standard Product Warranty Accrual	$3.05M-1.7%	$3.1M-33.8%	$4.68M+184%	$1.65M+178%
Contract Liabilities, Non-Current	$3.93M-33.4%	$5.9M+6.7%	$5.53M+208%	$1.79M-92.8%
Convertible Debt (Non-Current)	$645.38M-0.3%	$647.49M-27.4%	$892.24M-0.5%	$896.68M+0.1%
Accrued taxes and other expenses	——	——	——	——
Deferred revenue, net of current portion	$3.93M-33.4%	$5.9M+6.7%	$5.53M+208%	$1.79M-92.8%
Total debt	$57.04M+129%	$24.94M-40.2%	$41.69M-95.6%	$948.48M-0.7%
Common Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Common Stock Shares Issued	302M+2.6%	294.4M+10.0%	267.7M+18.2%	226.5M+2.5%
Convertible Preferred Stock Authorized Shares	50M0.0%	50M0.0%	50M0.0%	50M0.0%
Convertible Preferred Stock Issued Shares	0—	0—	0—	0—
Convertible Preferred Stock Outstanding Shares	0—	0—	0—	0—
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$302K+2.7%	$294K+9.7%	$268K+18.1%	$227K+2.7%
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	$0—	$0—
Preferred Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Unrealized Gains on Investments	$458K-23.9%	$602K-30.3%	$864K+5,300%	$16K—
Unrealized Losses on Investments (Before Tax)	$1K-99.4%	$180K-72.1%	$645K-86.5%	$4.78M—
Deferred Revenue Timing Percentage	——	——	——	——
Additional liability associated with indemnification obligations	$0—	$0—	$0—	$0—
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	$1K-99.4%	$180K-72.1%	$645K-86.5%	$4.78M—
Gross Unrealized Gains	$458K-23.9%	$602K-30.3%	$864K+5,300%	$16K—
1 Year or Less	——	——	——	——
After 1 Year through 5 Years	——	——	——	——
Common stock, par value (in dollars per share)	$00.0%	$00.0%	$00.0%	$00.0%
Common stock, shares authorized (in shares)	$1B0.0%	$1B0.0%	$1B0.0%	$1B0.0%
Common stock, shares issued (in shares)	$301.96M+2.6%	$294.42M+10.0%	$267.74M+18.2%	$226.51M+2.5%
Common Stock, Shares, Outstanding	$301.96M+2.6%	$294.42M+10.0%	$267.74M+18.2%	$226.51M+2.5%
Long-term debt, net	$645.38M-0.3%	$647.49M-27.4%	$892.24M-0.5%	$896.68M+0.1%
Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss	$279.05M-28.4%	$389.51M-38.3%	$631.2M-18.8%	$777.08M—
Estimated Fair Value	$279.51M-28.3%	$389.93M-38.2%	$631.42M-18.2%	$772.32M—
2031 and thereafter	——	——	——	——
Finite-Lived Intangible Assets, Accumulated Amortization	$406.42M+999%	$36.97M+287%	$9.56M+638%	$1.29M+240%
2028	——	——	——	$745K-11.1%
2030	——	——	——	$745K+1.6%
Remainder of 2026	——	——	——	——
2027	——	——	——	$853K-6.6%
2029	——	——	——	$745K+1.6%
Gross Carrying Amount	$421.54M+2.4%	$411.54M0.0%	$411.54M+3,467%	$11.54M+1.6%
Intangible asset, royalty rate utilized, discount rate	——	——	——	——
Royalty rate utilized, percentage	——	——	——	——
Intangible asset, weighted average cost of capital, discount rate, percentage	——	——	——	——
Raw materials	$38.64M-14.6%	$45.27M—	——	——
Consideration, capitalized	——	——	——	——
Present value of liability	——	——	——	——
Long-term restricted cash	$1.53M0.0%	$1.53M—	——	$2.92M-36.4%
Preferred Stock, Par or Stated Value Per Share	$00.0%	$00.0%	$00.0%	$00.0%
Preferred Stock, Shares Authorized	$50M0.0%	$50M0.0%	$50M0.0%	$50M0.0%
Preferred Stock, Shares Issued	$0—	$0—	$0—	$0—
Preferred Stock, Shares Outstanding	$0—	$0—	$0—	$0—
Standard and Extended Product Warranty Accrual	$3.05M-1.7%	$3.1M-33.8%	$4.68M+184%	$1.65M+178%
Remaining performance obligations related to customer contracts that are unsatisfied or partially unsatisfied	——	——	——	——
Short-term restricted cash	$20K-97.1%	$690K—	——	$300K-40.0%
Undiscounted effective interest method, effective interest rate, percentage	——	——	——	——
Remainder of Fiscal Year 2024	——	——	——	——
Remainder of Fiscal Year 2025	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Pacific Biosciences of California.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Pacific Biosciences of California's total assets?: Pacific Biosciences of California (PACB) holds $782.4M in total assets, down 9.1% year over year.
How much debt does Pacific Biosciences of California have?: Pacific Biosciences of California carries $59.3M in total debt against $2.4M of shareholders' equity, a debt-to-equity ratio of 25.06.
How much cash does Pacific Biosciences of California have?: Pacific Biosciences of California holds $57.9M in cash and equivalents.
Can Pacific Biosciences of California cover its short-term obligations?: Its current ratio is 5.65 — current assets exceed current liabilities.
Where does Pacific Biosciences of California's balance sheet data come from?: Every line is extracted from Pacific Biosciences of California's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.